BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006)
Phase 1
Completed
- Conditions
- Carcinoma
- Interventions
- First Posted Date
- 2009-07-20
- Last Posted Date
- 2016-03-22
- Lead Sponsor
- Bayer
- Target Recruit Count
- 158
- Registration Number
- NCT00941863
Bioequivalence Study: 2 mg Estradiol Valerate (EV) and 3 mg Dienogest (DNG) Without and With Levomefolate Calcium
Phase 1
Completed
- Conditions
- Pharmacology, Clinical
- Interventions
- Drug: BAY 86-7660,levomefolate calciumDrug: BAY 86-5027,Estradiolvalerate(EV) / Dienogest (DNG)Drug: BAY 98-7079, Estradiolvalerate (EV) / Dienogest (DNG) / Levomefolate calcium
- First Posted Date
- 2009-07-17
- Last Posted Date
- 2016-08-01
- Lead Sponsor
- Bayer
- Target Recruit Count
- 43
- Registration Number
- NCT00941057
Contrast-enhanced MRI in Children 2 Months to <2 Years
Phase 3
Completed
- Conditions
- Magnetic Resonance Imaging
- Interventions
- First Posted Date
- 2009-07-13
- Last Posted Date
- 2015-11-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 54
- Registration Number
- NCT00937391
Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI
- First Posted Date
- 2009-07-08
- Last Posted Date
- 2014-06-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 45
- Registration Number
- NCT00934882
FC Patch Low: Metabolism Study
Phase 2
Completed
- Conditions
- Contraception
- Interventions
- Drug: EE/Levonorgestrel (Microgynon, BAY86-4977)Drug: Gestodene/EE Patch (BAY86-5016)
- First Posted Date
- 2009-07-07
- Last Posted Date
- 2014-11-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 30
- Registration Number
- NCT00933179
EffeKt Taiwan- Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Taiwan
Completed
- Conditions
- Hemophilia A
- Interventions
- Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
- First Posted Date
- 2009-07-03
- Last Posted Date
- 2012-03-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 82
- Registration Number
- NCT00932555
Greatest International Antiinfective Trial With Avelox
Completed
- Conditions
- Bronchitis, ChronicBronchial Diseases
- Interventions
- First Posted Date
- 2009-07-03
- Last Posted Date
- 2012-11-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 50000
- Registration Number
- NCT00932802
Surveillance of Efficacy and Safety of Drug PRITOR in patieNts With Arterial Hypertension, Who do Not Tolerate ACE inhibitoR Treatment
Completed
- Conditions
- Hypertension
- Interventions
- Drug: Kinzal/Pritor (Telmisartan, BAY68-9291)
- First Posted Date
- 2009-07-03
- Last Posted Date
- 2010-04-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 3114
- Registration Number
- NCT00932867
Acceptability of Long-term Progestin-only Contraception in Europe
Completed
- Conditions
- Contraception
- Interventions
- First Posted Date
- 2009-07-02
- Last Posted Date
- 2013-12-24
- Lead Sponsor
- Bayer
- Target Recruit Count
- 436
- Registration Number
- NCT00931827
Evaluation of Cipro Inhale in Patients With Non-cystic Fibrosis Bronchiectasis
Phase 2
Completed
- Conditions
- Bronchiectasis
- Interventions
- Drug: Ciprofloxacin (Cipro, BAYQ3939)Drug: Placebo
- First Posted Date
- 2009-07-02
- Last Posted Date
- 2014-12-12
- Lead Sponsor
- Bayer
- Target Recruit Count
- 124
- Registration Number
- NCT00930982
© Copyright 2025. All Rights Reserved by MedPath